![conference banner](/images/conference-banner.jpeg)
Abstract
Neuroinflammation is a common characteristic of several mental health conditions such as major depression, bipolar disorder, post-traumatic stress disorder (PTSD) and schizophrenia (SCHZ). Inflammatory processes trigger and/or further deteriorate mental functions and are regarded as targets for therapeutic drug development. Cotinine is an alkaloid present in tobacco leaves and the main metabolite of nicotine. Cotinine is safe, non-addictive and has pharmacokinetic properties adequate for therapeutic use. Research has shown that cotinine has antipsychotic, anxiolytic, and antidepressant properties and modulates the serotonergic, cholinergic and dopaminergic systems. Consistent with the modulation of these neurotransmitter systems, cotinine behaves as a positive allosteric modulator of the nicotinic acetylcholine receptors (nAChRs) and has anti-inflammatory effects. The decrease in neuroinflammation induced by the stimulation of the cholinergic system seems to be a key element explaining the beneficial effects of cotinine in a diverse range of neurological and psychiatric conditions. This review discusses new evidence of the role of neuroinflammation as a key aspect in bipolar disorder, PTSD and major depression, as well as the potential use of cotinine to reduce neuroinflammation in those conditions.
Keywords: Neuroinflammation, Major depression, cotinine, Post-traumatic stress disorder, Bipolar disorder, suicide, anxiety.
Current Pharmaceutical Design
Title:Neuroinflammation: A Therapeutic Target of Cotinine for the Treatment of Psychiatric Disorders?
Volume: 22 Issue: 10
Author(s): Valentina Echeverria, J. Alex Grizzell and George E. Barreto
Affiliation:
Keywords: Neuroinflammation, Major depression, cotinine, Post-traumatic stress disorder, Bipolar disorder, suicide, anxiety.
Abstract: Neuroinflammation is a common characteristic of several mental health conditions such as major depression, bipolar disorder, post-traumatic stress disorder (PTSD) and schizophrenia (SCHZ). Inflammatory processes trigger and/or further deteriorate mental functions and are regarded as targets for therapeutic drug development. Cotinine is an alkaloid present in tobacco leaves and the main metabolite of nicotine. Cotinine is safe, non-addictive and has pharmacokinetic properties adequate for therapeutic use. Research has shown that cotinine has antipsychotic, anxiolytic, and antidepressant properties and modulates the serotonergic, cholinergic and dopaminergic systems. Consistent with the modulation of these neurotransmitter systems, cotinine behaves as a positive allosteric modulator of the nicotinic acetylcholine receptors (nAChRs) and has anti-inflammatory effects. The decrease in neuroinflammation induced by the stimulation of the cholinergic system seems to be a key element explaining the beneficial effects of cotinine in a diverse range of neurological and psychiatric conditions. This review discusses new evidence of the role of neuroinflammation as a key aspect in bipolar disorder, PTSD and major depression, as well as the potential use of cotinine to reduce neuroinflammation in those conditions.
Export Options
About this article
Cite this article as:
Echeverria Valentina, Alex Grizzell J. and Barreto E. George, Neuroinflammation: A Therapeutic Target of Cotinine for the Treatment of Psychiatric Disorders?, Current Pharmaceutical Design 2016; 22 (10) . https://dx.doi.org/10.2174/138161282210160304112511
DOI https://dx.doi.org/10.2174/138161282210160304112511 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Use of Oncolytic Vaccinia Viruses in the Treatment of Cancer: A New Role for an Old Ally?
Current Gene Therapy Pharmaceutical Strategies Enhancing Cell Penetration Efficiencies of Non-Viral Gene Delivery Systems
Current Gene Therapy Tumor-dependent Effects of Proteoglycans and Various Glycosaminoglycan Synthesizing Enzymes and Sulfotransferases on Patients’ Outcome
Current Cancer Drug Targets Nitrones: A Potential New Alternative as Therapeutic Agents
Current Organic Chemistry FOXM1 and its Oncogenic Signaling in Gastric Cancer
Recent Patents on Anti-Cancer Drug Discovery Comparing the Interaction of Cyclophosphamide Monohydrate to Human Serum Albumin as Opposed to Holo-Transferrin by Spectroscopic and Molecular Modeling Methods: Evidence for Allocating the Binding Site
Protein & Peptide Letters Cancer Stem-Cells Patents in the Context of their Therapeutic Purposes: Exploring the Latest Trends (2011-2015)
Recent Patents on Regenerative Medicine Advances in the Researches on the Biological Activities and Inhibitors of Phosphatidylinositol 3-kinase
Anti-Cancer Agents in Medicinal Chemistry Design and Synthesis of Tetrahydroisoquinoline Derivatives as Anti-Angiogenesis and Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry GPR55, a Lysophosphatidylinositol Receptor with Cannabinoid Sensitivity?
Current Topics in Medicinal Chemistry The Blood-Brain Barrier in Multiple Sclerosis: microRNAs as Key Regulators
CNS & Neurological Disorders - Drug Targets Sublethal Total Body Irradiation Leads to Early Cerebellar Damage and Oxidative Stress
Current Neurovascular Research Circular RNAs: Insights into Clinical and Therapeutic Approaches for Various Cancers
Current Protein & Peptide Science Synthetic Lethality to Overcome Cancer Drug Resistance
Current Medicinal Chemistry Role of Resveratrol in Modulating microRNAs in Human Diseases: From Cancer to Inflammatory Disorder
Current Medicinal Chemistry The Molecular Pathology of Eye Tumors: A 2019 Update Main Interests for Routine Clinical Practice
Current Molecular Medicine Implications of PEGylation of Carbon Nanotubes for Central Nervous System Bioavailability
CNS & Neurological Disorders - Drug Targets Overcoming Resistance of Glioblastoma to Conventional Cytotoxic Therapies by the Addition of PARP Inhibitors
Anti-Cancer Agents in Medicinal Chemistry The Long and Winding Road to Cancer Treatment: The Trail System
Current Pharmaceutical Design The Holy Grail of Polymer Therapeutics for Cancer Therapy: An Overview on the Pharmacokinetics and Bio Distribution
Current Drug Metabolism